|Videos|May 27, 2016
An Increased Emphasis on Individual Risk Factors and Goals
Advertisement
Episodes in this series
Zachary T. Bloomgarden, MD, MACE: We talked about lipid-lowering treatment and the notion that the idea of goals has recently been questioned. So, I certainly think that goals are a good way of treating cholesterol, but there are some controversies about that.
We use goals in treating all medical conditions. We use goals in treating blood pressure—we have to decide what the right blood pressure goal is for a given individual and then aim for that. We use goals in treating diabetes—we have to decide what the right A1C goal or fasting plasma glucose goal is for a given individual, and then stay with that. I’m completely in favor of the use of goals, as long as we do it in a rational fashion and apply it correctly.
Advertisement
Related to this article
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Congress's Mental Health TALK SAFE Act could expand telepsychiatry access by establishing permanent telehealth prescribing and licensing rules.
HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.
Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Advertisement
Advertisement
Trending on AJMC
1
Lung Cancer Progress Drives Down US Cancer Death Rates
2
All 50 States Apply for CMS's GENEROUS Model, With $64.3B in Savings Projected
3
FDA Approves Imlunestrant Plus Abemaciclib for Breast Cancer
4
Semaglutide Adherence Falls Once Out-of-Pocket Costs Top $75 a Month
5